Compare SOAR & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOAR | FEMY |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 12.0M |
| IPO Year | N/A | 2021 |
| Metric | SOAR | FEMY |
|---|---|---|
| Price | $0.14 | $2.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 1.2M | 43.3K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | N/A | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | $0.28 | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $0.10 | $0.29 |
| 52 Week High | $4.36 | $6.29 |
| Indicator | SOAR | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 44.90 |
| Support Level | $0.12 | $2.77 |
| Resistance Level | $0.19 | $4.22 |
| Average True Range (ATR) | 0.01 | 0.39 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 16.11 | 19.62 |
Volato Group Inc is an aviation technology company that connects travelers to private, on-demand flight access and develops proprietary software platforms for enterprise and operational applications. The company operates in a single operating and reportable segment, private aviation services. It operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.